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CASE REPORT
Treatment of a patient with severe cytomegalovirus (CMV) infection after
haploidentical stem cell transplantation with donor-derived CMV-specific T
cells
Joline Ingelsa,b, Saskia De Smetb, Kelly Heynsc, Nele Lootensb, Jonas Segaertd, Tom Taghona,
Georges Leclercqa, Karim Vermaelenc, Evelyne Willemse, Etienne Baudouxe, Tessa Kerrea,d, Frédéric Barone
and Bart Vandekerckhovea,b
aDepartment of Diagnostic Sciences, Ghent University, Ghent, Belgium; bCell Therapy Unit, Department of Regenerative Medicine, Ghent
University Hospital, Ghent, Belgium; cDepartment of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium; dDepartment of
Internal Medicine, Ghent University Hospital, Ghent, Belgium; eDepartment of Medicine, Division of Hematology, University of Liège,
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ABSTRACT
Objectives: Cytomegalovirus (CMV) infection is one of the most common complications in
allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. The classic antiviral treat-
ments have shown clinical efficacy but are often associated with drug resistance. Reconstitution
of CMV-specific cellular immunity is essential in controlling CMV infection; therefore, adoptive
transfer of CMV-specific T cells is a promising treatment option. We treated a patient with
a multidrug resistant CMV infection after haploidentical HSCT with CMV-specific T cells.
Methods: The T cells were derived from the HSCT donor who was CMV seropositive. We
generated the T cells by a short-term Good Manufacturing Practice (GMP) grade protocol in
which a leukapheresis product of the HSCT donor was stimulated with the immunodominant
antigen pp65 and interferon-γ secreting cells were isolated. A total of 5 × 105 T cells were
administered to the patient within 30 hours after leukapheresis.
Results: The patient was closely monitored for reconstitution of antiviral T cell immunity and
viral replication after adoptive T cell transfer. We observed an in vivo expansion of both CD4+
and CD8+ CMV-specific T cells associated with a significant decrease in viral burden and clinical
improvement.
Conclusion: This case report further supports the feasibility and effectiveness of adoptive
donor T cell transfer for the treatment of drug resistant CMV infections after allo-HSCT.
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Case report
Cytomegalovirus (CMV) infection has remained an
important cause of morbidity and mortality after allo-
geneic hematopoietic stem cell transplantation (allo-
HSCT). This is especially the case in recipients of HLA-
mismatched or HLA-haploidentical HSCT, as well as in
those given T cell depleted grafts [1–3]. Standard anti-
viral agents such as ganciclovir have significantly
reduced the incidence of early-onset CMV disease.
However, prolonged administration is associated with
significant hematopoietic toxicity, drug resistance,
delayed CMV-specific T cell reconstitution, and devel-
opment of late-onset CMV infection [4]. Previous
reports have demonstrated that T-cell immunity is
essential in controlling CMV infections [5]. Therefore,
a promising approach to treat refractory CMV infection
after allo-HSCT in patients who lack anti-CMV immu-
nity has been the adoptive transfer of CMV-specific
T cells from the original stem cell donor [6,7].
We here report the adoptive transfer of CMV-specific
T cells in a 9-year-old girl for the treatment of CMV
infection after allo-HSCT. The girl received CD34-
selected peripheral blood stem cells from her HLA-
haploidentical mother as treatment for a refractory neu-
roblastoma. Conditioning regimen consisted of melpha-
lan 140mg/m2, Thiotepa 10 mg/m2, fludarabine 200 mg/
m2 and thymoglobuline 10 mg/kg. The infused graft
contained 16.6 × 106 CD34+ cells/kg recipient with resi-
dual T cells of 0.02 × 106 CD3+ cells/kg recipient. She
experienced CMV infection 24 days after transplantation
(Figure 1.). Ganciclovir, foscavir and cidofovir all failed to
eradicate CMV infection and CMV sequencing demon-
strated a L773V substitution in the CMV polymerase
domain (a mutation known to cause resistance to ganci-
clovir, foscavir and cidofovir) [8].
Because of the rapid increase in viral load (Figure 1)
and the demonstration of the mutation in the CMV
polymerase domain, it was decided the treat the
patient with CMV virus-specific T cells of the mother
HSC donor on day 104 after transplantation. At the
same time, the patient was started on letermovir in
addition to cymevene + foscavir combination. The
CMV serostatus of the mother was repeated and
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confirmed to be seropositive: CMV IgM-, IgG+. Next, we
assessed the specific cellular immunity by quantifying
the peripheral blood T cells reactive to the immuno-
dominant antigen of CMV phosphoprotein-65 (pp65).
Isolated PBMC were incubated with Peptivator
CMVpp65, a 15-mer peptide pool covering the com-
plete primary structure of the pp65 antigen and sub-
sequently IFNγ production was visualized by
intracellular staining and flowcytometric analysis. We
detected a robust CMVpp65-specific CD4+ T cell
population (Figure 2(a)), while virtually no specific
CD8+ T cells were observed. The frequency of specific
CD4+ T cells was clearly above background (criterium:
at least twice background levels) and was considered
adequate to obtain a sufficient number of CMV-specific
T cells for adoptive transfer. An apheresis of the mother
was scheduled 4 days later.
As our patient was <18 years, she failed the inclu-
sion criteria of our clinical trial protocol (Eudra CT 2013-
004953-26). We therefore decided to perform the
Figure 1. Time course of viral load. CMV-DNA load was assessed in peripheral blood by PCR at different time points after HSCT.
Time point of infusion of CMV-specific T cells is indicated in the graph.
Figure 2. Detection of CMVpp65-specific T cells in PBMC and isolation from a leukapheresis of the family HSCT donor. (a) PBMC of
the HSCT donor were stimulated for 6 hours with CMVpp65 Peptivator and as a control without, intracellularly stained for IFNγ and
analyzed by flowcytometry. Dot plots represent IFNγ expression in the CD3+CD4+ or CD3+CD8+ population. (b) IFNγ expression in
CD3+ T cells and CD4+ and CD8+ T cell distribution before isolation and in the isolated fraction (final product). (c) Schematic
overview of the production process for the isolation of CMVpp65-specific T cells by the IFNγ Capture technology.
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procedure conforming to the hospital exemption pro-
cedure legislation and notified the federal agency for
medicines and health products (FAMHP) thereof. This
procedure is meant to enable the production of
a particular medicinal product specifically designed
for a particular patient for which no similar medicine
is available on the market. This allowed us to produce
the product in a timely fashion.
The leukapheresis product was collected from 7.7
liters of blood volume of the mother donor and con-
tained 5.7 × 109 nucleated cells. The leukapherate was
processed the following day using the CliniMACS cyto-
kine capture technology in a licensed Good
Manufacturing Practice (GMP) facility (Figure 2(c)).
Following a standardized production protocol, a total
of 1 × 109 nuclear cells were stimulated with Peptivator
CMVpp65 to induce IFNγ production. After 4 hours,
cells were labelled with a bispecific antibody
(Catchmatrix Reagent) that binds to the cells using its
CD45 specificity and is able to catch secreted IFNγ on
the cell membrane using its IFNγ specificity. After
a wash step and appropriate dilution, the coated cells
were incubated for exactly 45 minutes at 37°C to allow
for secretion of IFNγ and capture on the surface of the
cells by the Catchmatrix Reagent. Next, cells were
labelled with a second IFNγ-specific antibody coupled
to a magnetic bead resulting in bead covered
CMVpp65-specific T cells. The cell mixture was then
passed through a magnetic field to separate the bead-
coated CMVpp65-specific cells from the uncoated cells.
We recovered 5.4 × 105 viable CD3+ T cells, of which
2.7 × 105 were CD4+IFNγ+ and 0.1 × 105 CD8+IFNγ+
T cells (Figure 2(b)). The cells were washed and resus-
pended in Plasmalyte with 4% human serum albumin.
Total T cell dose was 24.4 × 103 T cells/kg patient. We
performed extensive quality testing on process
intermediates as well as on the final product.
Mycoplasma testing was performed using a PCR
method according to the European Pharmacopoeia
immediately after culture and proved negative.
Endotoxin levels were <4.4 IU/kg patient. Sterility test-
ing was performed on the apheresis product, after
Peptivator stimulation and on the final product.
However, as the definitive results were not available
at the time of release, a gram-stain was performed on
the final product and was negative. The whole produc-
tion process from stimulation to release was com-
pleted within 12 hours.
The CMV-specific T cells were infused intravenously
as a single dose on the same day of isolation, 114 days
after HSCT. There were no infusion-related acute toxi-
cities. Although donor and recipient are HLA-
haploidentical, no GvHD related to the T cell product
was induced up to 14 weeks after infusion.
Survival and in vivo expansion of CMVpp65-specific
T cells was assessed at 2, 4 and 8 weeks following
adoptive T cell transfer (Figure 3). CMV-specific CD4+
T cells were readily detectable in the peripheral blood
of the patient 2 weeks after infusion, and expanded
thereafter reaching a similar frequency as found in
CMV seropositive healthy individuals. This response
remained stable during the follow-up period of
8 weeks. Interestingly, although a low number of
CD8+ T cells were present in the T cell product
(Figure 2(b)), CMVpp65-specific CD8+ T cells strongly
expanded over time and even exceeded the frequen-
cies found in healthy CMV seropositive individuals at
8 weeks post-infusion. The expansion of CMVpp65-
specific T cells was accompanied by a significant reduc-
tion of CMV DNA copies in peripheral blood to <500
IU/ml blood which is the lower limit of detection of this
assay (Figure 1).
Figure 3. Expansion of CMVpp65-specific T cells after adoptive T cell transfer. CMVpp65-specific T cell response was assessed in
peripheral blood of the recipient at 2, 4 and 8 weeks after adoptive T cell transfer. PBMC were stimulated with CMVpp65 Peptivator
for 6 hours and intracellularly stained for IFNγ. The percentage of IFNγ+ T cells obtained after stimulation with CMVpp65 Peptivator
was corrected for background staining by subtracting the percentage of IFNγ+ cells measured in the absence of stimulation.
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Discussion
In this case report, we describe the successful adoptive
transfer of CMV-specific T cells derived from
a haploidentical HSCT family donor in a patient with
a refractory CMV infection after HSCT.
The successful production and transfer of CMV-
specific T cells requires a suitable donor, a validated pro-
duction protocol and coordinated logistics. As our patient
presented with a life-threatening CMV infection, the cell
therapy product had to be administered as rapidly as
possible. Therefore, the throughput time from donor
screening to collection of apheresis and infusion of the
T cells had to beminimized. From themoment the intent
to treat was decided, it took 2 days to screen the donor
for CMV-specific T cells and another 2 days for the apher-
esis and isolation of the cells. The final product was
transported immediately after production to the trans-
plant centre and administered within 4 hours after pro-
duction. This very short throughput time is only possible
when fully validated procedures and trained dedicated
production and QC personnel is available at all time. In
addition, for the isolation of the T cells, we applied the
GMP-compatible IFNγ Capture technology in which the
CMV-specific T cells are directly isolated from
a leukapheresis without the need for prolonged cultures.
This technology allowed us to isolate the T cells and
release the product within one day after the apheresis.
We administered a low dose of 24.4 × 103 T cells/kg
body weight and observed an expansion of CMV-
specific T cell immunity, associated with a strong
reduction in CMV copies. Clinical effects with low
T cell doses have also been observed in a study by
Feuchtinger et al., in which haploidentical T cells admi-
nistered at a median dose of 7.1 × 103 T cells/kg were
associated with strong reductions in CMV viremia [6].
As in our case, these low doses did not result in GvHD,
which is a potential life-threatening toxicity when
administering T cells in a haploidentical setting.
CMV-specific T cell immunity has been demon-
strated to be crucial in the effective control of CMV
infection in posttransplant patients. After T cell infu-
sion, we observed an expansion of both CD4+ and
CD8+ T cells. Cytotoxic CD8+ T cells destroy virus-
infected cells, while helper CD4+ T cells regulate the
induction of effector CD8+ T cells and maintenance of
CD8+ T memory cells [9,10]. Multiple studies suggest
that functionality of both T cell subsets is required to
achieve an effective control of CMV infection [11,12].
The strong reduction of CMV copies we observed is
thus most likely attributable to the combined recon-
stitution of CD4+ and CD8+ T cell immunity. Of note,
the viral load in blood was already decreasing at the
time of T cell infusion following the introduction of
letermovir. Eighteen days before infusion the patient
had profound T-lymphopenia (4.9 CD3+/µl with no
detected naive CD4+ T cells) and T cell counts normal-
ized concurrent with the clearance of the CMV infec-
tion, to 452 CD3+/µl 3 days after infusion and 2077
CD3+/µl 1 month after T cell infusion. We believe that
the increase in peripheral T cell levels is a consequence
of the viral clearance and of peripheral expansion of
infused T cells in this context of profound lymphope-
nia. Further, it is unlikely that the posttransplant-
generated naïve T cells would contain such a high
percentage of CMV reactive T cells at the measured
time points. It is therefore implausible that endogen-
ous reconstitution of CMV reactive T cells contributed
to the decrease in viral load.
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